/content/dam/www/people-profile-photos/u/masumi-ueda-oshima/provider-masumi-ueda-directory-1x.jpg
/content/dam/www/people-profile-photos/u/masumi-ueda-oshima/provider-masumi-ueda-directory-2x.jpg
Ueda Oshima
Masumi Ueda Oshima, MD, MA
Top Doctor icon

Masumi Ueda Oshima, MD, MA

Hematology-Oncology

  • Medical Director, Inpatient Blood and Marrow Transplantation and Immunotherapy Service, Fred Hutch
  • Associate Professor, Clinical Research Division, Fred Hutch
  • Affiliate Investigator, Translational Science and Therapeutics Division, Fred Hutch
  • Associate Professor, Division of Hematology and Oncology, University of Washington School of Medicine
Request an Appointment

About

Dr. Masumi Ueda Oshima is a board-certified physician and researcher at Fred Hutch, providing blood and marrow transplantation to patients with blood cancers. She studies ways to prevent complications after transplant.

Background

Dr. Ueda Oshima cares for patients with blood cancers such as leukemia and myelodysplastic syndrome. She specializes in blood and marrow transplant (BMT) and on managing complications that can occur after transplant, including graft versus host disease (GVHD), a condition in which donor immune cells attack a patient’s tissues. She also provides care in the Long Term Follow Up Program, supporting patients after BMT.

In parallel with patient care, Dr. Ueda Oshima conducts research focused on preventing complications after BMT, including GVHD and disease relapse. Her work aims to improve long term outcomes and quality of life for people who undergo BMT.

Area of Clinical Practice
Adult blood and marrow transplantation

“My goal is to make a shared decision in situations that are often difficult.”

— Dr. Ueda Oshima

What drew you to oncology?

Medicine is a unique field where science and the humanities intersect. During one summer in college, I worked in a clinic in Cleveland and I really enjoyed the opportunity to meet people, hear their stories and try to help them. My decision to go into cancer care was influenced by a mentor I had in medical school who gave a lecture on cancer biology and the development of imatinib, one of the first targeted drug therapies for cancer. Later, I had the opportunity to follow this same professor in an outpatient clinic, where I experienced the privilege of helping patients facing this disease. From that moment on, I never considered any other specialty.

What’s it like to work with you?

Treatment is a highly individualized pursuit on multiple levels, from the molecular to the humanistic; it should cater to your biology, unique situation, beliefs and life experiences. I strive to get to know who you are, educate you about your disease and treatment options and provide as much guidance as possible. I’m hopeful about the future of blood and bone marrow transplantation. While not every person is a good candidate for these procedures, we are constantly working to innovate new approaches and improve outcomes so that one day we can provide a cure for every patient.

Diseases Treated

Leukemia

Myelodysplastic Syndrome

Research Interests

Reduced-intensity and nonmyeloablative conditioning regimens

Prevention and treatment of graft-vs-host disease

Acute myeloid leukemia and myelodysplastic syndrome

Languages

English
Japanese

Education and Experience

Fellowship, Hematology-Oncology, University Hospitals Case Medical Center, Case Western Reserve University, 2013-2016

Residency, Internal Medicine, University of Washington, 2010-2013

MD, Case Western Reserve University, 2010

BA, Biology; MA, Bioethics; Case Western Reserve University, 2006

Board Certification

Hematology, 2016; Internal Medicine, 2013; American Board of Internal Medicine

Awards

Seattle Magazine's 2025 Top Doctors Award
Dr. Oshima has received this peer-nominated award for exceptional patient care.

Clinical Trials

We make promising new treatments available to you through studies called clinical trials led by Fred Hutch physicians and researchers. Many of these trials at Fred Hutch have led to FDA-approved treatments and have improved standards of care globally. Together, you and your physician can decide if a study is right for you.

Find a Clinical Trial Led by Dr. Ueda Oshima

Publications

Many of our Fred Hutch physicians and researchers conduct ongoing research to improve standards of patient care. Their work is evaluated by other doctors and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this Fred Hutch physician has written.

View Dr. Ueda Oshima's Publications

Your Care Team

At Fred Hutch, you receive care from a team of providers with extensive experience in your disease. Your team includes physicians, a patient care coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like registered dieticians, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.

Meet Other Providers

Insurance

Fred Hutch accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

More About Insurance

Stories

All news
Fred Hutch hematologists featured at 2026 Tandem Meetings
Fred Hutch hematologists featured at 2026 Tandem Meetings Researchers highlight findings on making stem cell transplants safer and more effective March 9, 2026
Novel regimen greatly reduced chronic GVHD in phase 2 study at Fred Hutch
Novel regimen greatly reduced chronic GVHD in phase 2 study at Fred Hutch Substituting cyclophosphamide for a standard post-transplant immunosuppressant is a “gamechanger” February 7, 2025
Surprising findings about blood cell mutations bode well for transplant recipients
Surprising findings about blood cell mutations bode well for transplant recipients Fred Hutch researchers compared blood samples from 16 recipient-donor pairs, some more than 45 years after transplant January 10, 2025

Contact Information

206.667.4546

206.667.6124